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Abstract
Adherence to antiretroviral medication in the treatment of HIV is critical, both to maximize efficacy and to 
minimize the emergence of drug resistance. The aim of this prospective study in three public hospitals in KwaZulu-
Natal, South Africa, is to assess the use of Traditional Complementary and Alternative Medicine (TCAM) by HIV 
patients and its effect on antiretroviral (ARV) adherence 6 months after initiating ARVs. 735 (29.8% male and 
70.2% female) patients who consecutively attended three HIV clinics completed assessments prior to ARV initiation 
and 519 after six months on antiretroviral therapy (ART) Results indicate that the use of herbal therapies for HIV 
declined significantly from 36.6% prior to antiretroviral treatment (ART) initiation to 7.9% after being on ARVs for 
6 months. Faith healing methods, including spiritual practices and prayer for HIV declined from 35.8% to 22.1% and 
physical/body-mind therapy (exercise and massage) declined from 5.0% to 1.9%. In contrast, the use of 
micronutrients (vitamins, etc.) significantly increased from 42.6% to 87.4%. In multivariate regression analyses, 
ARV non-adherence (dose, schedule and food) was associated with the use of herbal treatment, not taking 
micronutrients and the use of over-the-counter drugs. The use of TCAM declined after initiating ARVs. As herbal 
treatment for HIV was associated with reduced ARV adherence, patients’ use of TCAM should be considered in 
ARV adherence management. 
Key words: Traditional, complementary, alternative medicine, antiretroviral treatment adherence, HIV patients, 
KwaZulu-Natal, South Africa.
Introduction
Traditional, complementary and alternative medicine (TCAM)  broadly comprises herbal remedies, spiritual 
practices and prayer, traditional Chinese medicines, acupuncture, acupressure, chiropractic care, massage therapy,  
meditation, visualization, therapeutic touch and micronutrients (vitamins, minerals, and multivitamins). TCAM has 
been demonstrated to be widely used by people living with HIV (PLHIV), both on and off therapy with ARVs in 
many different settings (e.g., Langlois-Klassen et al., 2007; Ma et al., 2008; Peltzer et al., 2008; Reid et al., 2008). In 
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a study in KwaZulu-Natal, South Africa, TCAM was commonly used for HIV in the past six months by study 
participants (317, 51.3%) and herbal therapies alone (183, 29.6%) prior to ART initiation. The use of micronutrients 
(42.9%) was excluded from TCAM since mostly vitamins were provided by the health facility. Herbal therapies were 
mainly used for pain relief (87.1%) and spiritual practices or prayer for stress relief (77.6%) (Peltzer et al., 2008).
Babb et al. (2007) studied individuals (n=44) with moderate or advanced HIV disease attending a workplace clinic 
providing ART in South Africa, and found that 32% were using traditional medicines, most frequently African 
potato (9/14) and Aloe vera (3/14), and Malangu (2007) found among HIV-infected patients on ART (n=180) in 
Pretoria, South Africa, that 4.4% used African traditional medicine and 3.3% complementary and alternative 
medicines.
There is data to suggest that TCAM impacts on ARV adherence, although the data is variable and findings 
are not consistent across studies.  Littlewood and Vanable (2008) reviewed TCAM use and ART adherence among 
PLHIV and only two out of the seven studies identified had found an association between TCAM use and ART 
nonadherence. Jernewall et al. (2005) found that in a sample of HIV-positive Latino gay and bisexual men in the 
USA, users of Latino complementary and alternative medicines (CAM) were less likely to attend medical 
appointments and had lower rates of HAART adherence than users of Asian CAM (available within the clinics). The 
second study, also in the USA, found that HIV infected women (mostly African-American) who used TCAM  such 
as vitamins and immunity boosters were more likely to report ART nonadherence in the past 30 days (Owen-Smith
et al., 2007). 
In the 40 studies reviewed, TCAM use was associated with greater HIV symptom severity and a higher 
degree of disability among PLHIV (Littlewood and Vanable, 2008). Patients with a greater desire for medical 
information and involvement in medical decision making and with a negative attitude toward antiretrovirals were 
more likely to use TCAM (London et al., 2003), and one-third had not discussed such use with their health care 
provider (Hsiao et al. 2003). TCAM disclosure rates to health care providers varied from 38% to 90% across studies 
(Littlewood and Vanable, 2008).
There seem to be no studies on the use of TCAM and its impact on ART adherence in Africa. Therefore, the 
aim of this prospective study is to assess HIV patients’ use of TCAM and its effect on ARV adherence 6 months 
after commencing ARVs at three public hospitals in KwaZulu-Natal, South Africa.
Methods
This is a prospective study of all treatment-naϊve patients (N = 735, Extra patients (ARV-naïve) were 
recruited to increase the initial baseline cohort sample size of 618) recruited from all three public hospitals in 
Uthukela health district in KwaZulu-Natal from October 2007 to February 2008. All ARV-naϊve patients who were 
about to commence ARVs (18 years and above) and who consecutively attended the HIV clinics during the 
recruitment period were eligible for this study. Details about the setting, sampling procedure and recruitment have 
been described elsewhere (Peltzer et al., 2008). Patients at six months follow-up were interviewed at the clinic. 
Patients who failed to attend for planned follow-up were contacted by telephone and up to two home visits.
Measures
Patients were interviewed with an anonymous questionnaire that requests information on sociodemographic 
characteristics, clinical history and health-related characteristics, TCAM use and health beliefs. Following initiation 
of ARVs, information on side effects, and changing or interrupting ART was also obtained. Clinical data relating to 
date of HIV diagnosis, HIV acquisition and transmission risk factors, current CD4 cell count, viral load (Chiron 3.0 
bDNA), opportunistic infections, HIV and non-HIV medications was obtained from the medical chart. The use of 
TCAM was assessed with questions on 8 different TCAM methods over the past six months, the duration of usage, 
costs and the awareness of the health care provider of using TCAM.
The Revised Sign and Symptom Checklist for Persons with HIV Disease
The SSC-HIVrev is a 72-item checklist of HIV/AIDS specific physical and psychological symptoms, scored 
using the following scale: 0 = not present today, 1 = mild, 2 = moderate, 3 = severe (Holzemer et al. 2001). Female-
specific symptoms were removed, reducing the total to 64 (v. Peltzer et al. 2008). An HIV symptom index (symptom 
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intensity) was created which weights each symptom’s presence (0 or 1) by a rating of 1–3 (mild, moderate or severe). 
Cronbach’s alpha of this scale for this sample was .084.
Health-Related Quality of Life
The WHOQOL-HIV BREF is based on the WHOQOLHIV measure, one of the two World Health 
Organization’s QoL instruments for use with HIV-infected populations. In this analysis only the individual 
respondent’s overall QoL and general health perception measured directly with ‘How would you rate your quality of 
life?’ (ranging from ‘very poor’ to ‘very good’) was used (WHO, 2002).
HIV knowledge and patient-provider variables
Participants' HIV-related knowledge and orientation towards treatment information were assessed with two 
indicators. Self-assessed knowledge about HIV/AIDS was measured with a single item, "How well-informed do you 
rate yourself to be about HIV disease and treatment relative to most people who are HIV positive?" Response options 
were 1 = much better informed than most to 5 = much less informed than most. Responses indicating that they 
perceived themselves to be "much better informed than most" and "somewhat better informed than most" were 
categorized as better informed (vs. those who viewed themselves as being "about as well informed," "somewhat less 
informed", or "much less informed") (London et al., 2003). The desired level of information involvement was 
assessed with two items, e.g. "I want to take an active role in the medical management of my HIV infection and its 
complications." Response options were 1 = strongly agree to 4 strongly disagree. These items were combined into a 
4-point scale in which higher scores indicate a stronger desire for information (London et al., 2003). Cronbach’s 
alpha for this information desire index was .68 for this sample.
Participants' degree of trust in medical providers was measured with two items, e.g. "How much do you 
trust your doctor or clinic to offer you high-quality medical care?" Response options were from 1 = completely to 5 
= not at all. Responses to these questions were reversed, combined, and placed on a scale ranging from 0 to 100, in 
which higher scores indicate higher trust (London et al., 2003). Cronbach’s alpha for this trust in medical providers' 
index was 0.76 for this sample.
Desired level of decision involvement reflected the extent to which participants wanted to be involved in 
medical decision making, e.g., "It is better to trust a doctor or a nurse in charge of a medical procedure than to 
question what they are doing". Response options were 1 = strongly agree to 4 strongly disagree. These items were 
combined into a 4-point scale in which higher scores indicate a stronger disagreement (i.e., greater desire for 
involvement in decisions about medical care) (London et al., 2003).  Cronbach’s alpha for this desire for 
involvement in decisions index was .79 for this sample.
The experience of discrimination in the health care system was assessed with 3 items, e.g. "Has anyone in 
the health care system ever exhibited hostility or a lack of respect toward you?" Response options were "yes" or 
"no". If the participant answered "yes" to any of the three items, he or she was coded has having experienced 
discrimination (London et al., 2003). Cronbach’s alpha for this health care provider discrimination index was .63 for 
this sample.
Adherence assessment
ARV treatment adherence was assessed by two self-reported adherence measures - the Adult AIDS Clinical 
Trials Group (AACTG) adherence instrument and the 30-day visual analog scale (VAS). The AACTG consists of 
nine questions that assess adherence from the previous 1-4 days, within the past week, prior to the interview. The 
instrument also assesses reasons for non-adherence (Chesney et al., 2000). The 30-day visual analog scale (VAS) 
provided an overall adherence assessment for a longer time interval. Both have been validated in resource-limited 
settings (Maneesriwongul, 2006; Sarna et al., 2005). Adherence is calculated as the % of doses taken over those 
prescribed. Adherence levels assessed from the VAS are defined as follows: full adherence = 100%, partial 
adherence >/= 95% and < 100%, and non-adherence as < 95% of prescribed doses taken since the last refill. 
Dose adherence was assessed by asking participants to report on how many days they had missed taking all 
their doses during the past 4 days. Dose non-adherence was defined as having missed all doses on at least one day 
during the past 4 days.
Adherence to scheduling was measured by the question “Most anti-HIV medications need to be taken on a 
schedule, such as ‘2 times a day’ or ‘3 times a day’ or ‘every 8 hrs.’  The participants were asked to report how 
closely they followed their specific schedule over the last 4 days using a 5-point Likert scale, ranging from “never” 
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to “all the time.” Schedule non-adherence was defined as having missed scheduling in the past 4 days. Adherence to 
dietary instructions was measured by first asking “Do any of your anti-HIV medications have special food 
instructions, such as ‘take with food’ or ‘on an empty stomach’ or ‘with plenty of fluids’?” If the response was “yes,” 
participants were asked to rate how often they had followed dietary instructions over the last 4 days using a 5-point 
Likert scale, ranging from never” to “all the time.” Schedule non-adherence was defined as having missed 
scheduling in the past 4 days. Food non-adherence was defined as not having followed special instructions over the 
last 4 days.
Data analysis
Data were analyzed using Statistical Package for the Social Sciences (SPSS) for Windows software application 
programme version 17.0. Frequencies, means, standard deviations, median, interquartile range, were calculated to 
describe the sample. Bivariate analyses were conducted to examine the relationships between overall TCAM use, 
herbal remedy use and socio-demographic variables, health characteristics, ART adherence and further health-
seeking behaviour variables. Multivariate logistic regression included in the model All variables statistically 
significant at the 5% level in bivariate analyses were included in the multivariate model. No significant interactions 
were found between socio-demographic variables health-seeking behaviour and health characteristics. In multivariate 
regressions, adjustment was made for site of care, to account for variations in practice patterns and demographic 
differences across sites.
Results
Of 735 patients (29.8% male and 70.2% female) who completed assessments prior to initiation of ARVs, 
525 were able to complete the assessment at six months follow-up. Of the original cohort, 75 had died, 57 had been 
transferred, 54 could not be traced, 23 refused the interview and 1 interview was incomplete. At six months 
following proposed ARV initiation, 519 patients started therapy and six failed to start treatment. Over the six month 
period 24 patients (4.6%) had temporarily suspended ARVs because of side effects, and three (0.6%) had changed 
their ARVs. HIV medications for 411 (79.8%) patients included Lamivudine (3TC), Starivudine (d4T) + efavirenz 
(Stocrin) and for 107 (20.8%) Lamivudine (3TC), Starivudine (d4T) + nevirapine.
Socio-demographic characteristics
Nearly three-quarters (73.5%) of the 519 patients who had initiated ARVs in this sample were female, 
62.2% of whom were between 30 and 49 years old. Nearly three-quarters (73.3%) were never married, 61.9% had 
Grade 8 or higher formal education, almost all (98.8%) were Zulu and the largest religious affiliation was 
charismatic churches (38.5%). The majority of the sample (61.7%) lived in rural areas and was unemployed (59.6%). 
Only 31.7% of respondents had a formal salary as their main source of household income, 52.5% was in receipt of a 
disability grant and 15% had health insurance (Table 1).
Health characteristics
Most patients (75.2%) had been diagnosed with HIV in the year prior to study recruitment. The median 
CD4 count at follow-up was 130 cells/cu.mm compared to 119 cells/cu.mm prior to ARV initiation. The mean 
number of HIV symptoms reported at follow-up was 1.21, 6.6% of patients were receiving TB treatment, 10.3% had 
at least one hospital admission in the past six months, and 25.6% had seen an ARV treatment buddy at least once in 
the past six months. Over three-quarters of patients (76.3%) felt that they were better informed than most about HIV 
and HIV treatment, with 66.2% reporting to have a complete understanding of T-helper (CD4) count. The majority 
of respondents (60.5%) had a high health information involvement score (3.5 or above), 61.9% had a high degree of 
trust in their medical care provider (90 or more), and 43% reported a moderate health care decision involvement 
score. Only very few (2.1%) reported any experience of discrimination in their health care system (Table 2).
TCAM use
The use of herbal therapies for HIV declined significantly from 36.6% prior to ARV initiation to 7.9% after 
6 months on ARVs. Faith healing methods (including spiritual practices and prayer) declined from 35.8% to 22.1% 
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and physical/body-mind therapy (exercise and massage) declined from 5.0% to 1.9%.  In contrast, the use of 
micronutrients (vitamins, etc.) significantly increased from 42.6% to 87.4%. At baseline, only 10.2% of patients 
reported that their health care provider was aware of their herbal remedy use. This figure declined to 4.7% after 6 
months on ARVs. Patients were more willing to disclose faith healing methods than herbal remedies to their health 
care provider, with the disclosure rate increasing from 16.1% at baseline to 50.4% at follow-up (Table 3).
Table 1: Sample characteristics
Variable N=519 %
Sex
   Male
   Female
139
370
26.6
73.4
Age in years
   18-29
   30-39
   40-49
   50 and above
136
222
100
59
26.3
42.9
19.3
11.4
Marital status
   Never married
   Currently married
   Cohabitating
   Divorced/separated
   Widowed
379
68
40
11
19
73.3
13.2
7.7
2.2
3.7
Highest education
   None
   Up to Grade 7
   Grade 8-11
   Grade 12 or more
40
157
221
99
7.7
30.4
42.7
19.1
Ethnicity
   Zulu
   Other
513
6
98.8
1.2
Religious affiliation
   African/traditional
   Christian (Protestant churches)
   Christian (Catholic)
   Apostolic
   Zion Christian Church
   Other
   No religion
52
73
49
48
152
71
74
10.0
14.1
9.4
9.2
29.3
14.0
14.3
Residence
   Rural village
   Informal settlements (slums)
   Urban/metropolitan areas
   Township
    Farm
42.7
6.0
9.5
22.8
19.0
Employment situation
   Housewife, home maker
   Unemployed
   Employed
   Pensioner, student, disabled
76
303
115
21
15.0
59.6
22.6
4.2
Main source of household income
   Formal salary
   Contribution by family members
   Government grant
   Grants/donations by private welfare organizations
   No income (other than social grant)
   Other
162
86
113
80
38
32
31.7
16.9
22.1
15.7
7.4
6.3
Disability grant (“for HIV/AIDS”)
Yes
  No
268
242
52.5
47.5
Health insurance
  Yes 77 15.0
Peltzer et al.,  Afr. J. Trad. CAM (2010) 7 (2): 125 - 137 130
   No 438 85.0
At follow-up the main reason for using herbs for HIV was for immune supplementation (66.7%). Faith 
healing methods were mainly used to improve overall well-being (51.1%) and for stress relief (22.1%). Only 8 
(1.5%) respondents believed that it was possible to treat HIV with TCAM alone.
ART adherence
Using the 30-day visual analog scale (VAS) 427 patients (82.9%) were 95% adherent in the month prior to 
the survey. Results from the AACTG adherence instrument found that on the 4-day recall dose adherence, 15.5% of 
patients were non-adherent (having missed at least one full day of medication in the past four days). 70.8% of 
patients were adherent to all parameters (dose, schedule and food) (Table 4).
Table 2: Health characteristics
Variable N=519 %
Time since HIV diagnosis
   2007/8
   2006-1995   
379
125
75.2
24.8
CD4 count (cells/uL)= Median=130 (IQR=72-185)
(at baseline: Median=119; IQR=59-163) 
   1-99
   100-200
   >200 
188
232
85
37.2
45.9
16.8
Number of HIV symptoms (range 0-20) M(SD) 1.21 (2.60)
Receiving TB treatment 34 6.6
Hospital admission in the past 6 months 53 10.3
Participated in support group in the past 6 months 14 2.7
Seen someone for counseling/support in the past 6 months 123 23.8
Seen an ARV treatment buddy in the past 6 months 132 25.6
Understanding (complete) of T-helper (CD4) count 337 66.2
HIV disease & HIV treatment related knowledge (better informed 
than most)
392 76.3
Health information involvement score
   4.0
   3.5-3.9
   <3.5
203
108
203
39.5
21.0
39.5
Degree of trust in medical provider score
   100
   90-99
   0-89
219
99
196
42.6
19.3
38.1
Health care decision involvement score
   1.0
   1.5
   2 or more
205
88
221
39.9
17.1
43.0
Discrimination by health care provider 14 2.1
Bivariate and multivariate regression analyses found that the use of herbal treatment, not using 
micronutrients (available from clinics), the use of over-the-counter drugs and overall TCAM use (herbs, faith healing 
and massage/exercise) were associated with VAS as well as dose, schedule and food non-adherence. The use of faith 
healing methods and massage/exercise was associated with neither VAS nor dose, schedule and food non-adherence 
(Table 5). The main reasons for having missed ARV medications were “being away from home” (9.9%), followed by 
“wanted to avoid side effects” (7.6%),  felt sick or ill (7.4%) and felt good (6.4%) (Table 6).
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Table 3: Use of TCAM (Traditional, complementary and alternative medicine) for HIV in the past six months 
(prior to ART=Time 1(T1), N=735; follow-up (T2), N=525)
Use duration 
in weeks
Cost in 
Rand/month
Health care provider 
aware of use
N % M (SD) M (SD) n (%)
Total TCAM usea T1
T2
421
144
42.6
28.0
1. Herbal therapies 
(e.g., Ginseng, 
Echinacea or St. John’s 
Wort, Hypoxis plant 
(African potato), 
cannabis)
T1
T2
269
43
36.6
8.0
10.0 (8.1)
4.0 (1.5)
129 (166)
250 (330)
21 (10.2)
2 (4.7)
2. Faith healing 
including spiritual 
practices and prayer
T1
T2
263
116
35.8
22.1
11.9 (7.0)
19.8 (18.6)
0.4 (1.0)
0.2 (1.7)
42 (16.1)
58 (50.4)
3. Physical/body-mind 
therapy (e.g. exercise, 
massage)
T1
T2
37
10
5.0
1.9
13.5 (14.8)
8.9 (6.7)
9 (11)
0.8 (2.6)
2 (0.5)
6 (60.0)
4. Micronutrients 
(vitamins, minerals & 
multivitamin)
T1
T2
312
457
42.6
87.4
12.5 (9.5)
18.3 (12.4)
6 (53)
8 (20)
173 (66.3)
449 (98.3)
5. Over-the-counter 
drugs
T1
T2
15
48
2.1
6.5
14.2 (14.1)
4.8 (2.1)
159 (202)
23 (22.3)
4 (22.2)
28 (58.3)
a The use of micronutrients was excluded from TCAM since mostly vitamins were provided by the health facility
Table 4: ART adherence
n %
30-day VAS at 95% Adherent
Non-adherent
427
88
82.9
17.1
Self-reported 4-day recall dose adherence Adherent
Non-adherent
435
80
84.5
15.5
Self-reported time adherence Adherent
Non-adherent
372
142
72.4
27.6
Self-reported food adherence Adherent
Non-adherent
369
146
71.7
28.3
Adherence to all (Dose, Schedule and Food) Adherent
Non-adherent
364
150
70.8
29.2
Determinants of herbal treatment and overall TCAM use
Bivarate analysis found that herbal treatment use for HIV was associated with rural residence, being on a 
disability grant, lower reported overall quality of life, missing ARVs in order to avoid side effects, an understanding 
of CD4 count, better self-reported HIV disease and treatment knowledge, lower health care information involvement 
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score, higher health care decision involvement score and having seen an ARV treatment buddy or a counsellor at 
least once in the past six months. In multivariate analysis having missed ARV medication in order to avoid side 
effects and being on a disability grant were significant predictors of the use herbal treatment for HIV.
In bivariate analyses overall TCAM use was associated with younger ages, higher educational level, lower 
self-reported quality of life, missing ARVs in order to avoid side effects, better self-reported HIV disease and 
treatment knowledge, lower health care information involvement score, lower degree of trust in medical provider 
score, higher decision involvement score and having seen an ARV treatment buddy or counselor. In multivariate 
analysis, higher education, lower self-reported quality of life, a lack of understanding of CD4 count, higher self-
reported HIV disease and treatment related knowledge and higher health care decision involvement were significant 
predictors of TCAM use for HIV (Table 7).
Table 5: Association between TCAM use and antiretroviral non-adherence
VAS non-adherence (<95%) Dose, schedule and food non-adherence
Cr OR, 
95% CI
P Adj OR*, 
95% CI#
P Cr OR*, 
95% CI
P Adj OR*, 
95% CI##
P
1. Herbal treatment 7.99 (3.98-
16.01)
.000 6.67 (3.12-
14.24)
.000 22.62 (8.67-
59.02)
.000 28.62 (10.02-
81.76
.000
2. Faith healing 0.84 (0.47-
1.50)
.549 --- 0.56 (0.34-
0.93)
.026 0.41 (0.20-
0.82)
.012
3. 
Massage/Exercise
3.06 (0.70-
13.62)
.136 --- 4.16 (0.98-
17.61)
.053 ---
4. Micronutrients 0.20 (0.11-
0.35)
.000 0.19 (0.10-
0.34)
.000 0.06 (0.03-
0.13)
.000 0.06 (0.03-
0.12)
.000
5. Over-the-counter 
drugs
3.97 (1.74-
8.28)
.001 2.38 (0.92-
6.16)
.073 9.90 (4.16-
23.54)
.000 10.51 (3.80-
29.07)
.000
Combined TCAM 
(1,2,3)
2.18 (1.34-
3.56)
.000 1.52 (1.00-
2.30)
.049
*Adjusted for age, sex and education
#Nagelkerke R square=.21; ## Nagelkerke R square =.43
Table 6: Reasons for missing ARV medications
Rarely or sometimes
(N=519)
%
1. Were away from home? 54 9.9
5. Wanted to avoid the side effects? 39 7.6
10. Felt sick or ill? 38 7.4
14. Felt good? 33 6.4
4. Had too many pills to take? 27 5.3
2. Were busy with other things? 22 4.3
13. Ran out of pills? 22 4.3
9. Fell asleep / slept through dose time? 20 3.9
12. Had problems taking pills at specified times (with meals, on 
empty stomach etc)?
20 3.9
3. Simply forgot? 15 2.9
11. Felt depressed or overwhelmed? 13 2.5
8. Felt like the drug was toxic / harmful? 10 2.0
7. Had a change in daily routine? 8 1.6
6. Did not want others to notice you taking medication? 3 0.6
Discussion
In this South African HIV patient cohort, the use of herbal therapies for HIV prior to initiation of ARVs 
declined significantly from 36.6% prior to ART initiation to 8.0% after being on ARVs for 6 months.  The level of 
reported use of herbal therapies by PLHIV in Africa varies across studies, however, the decline in use of herbal 
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Table 7: Odds ratios (ORs) and 95% confidence intervals (95% CIs) for herb use and TCAM use, bivariate and multivariate  analyses
Bivariate analyses Multivariate analyses
Herb use TCAM use Herb use TCAM use
Variable % Cr OR (95% CI) P % Cr OR (95% 
CI)
P Adj OR 
(95% CI)
P Adj OR (95% CI) P
Sex
   Female (n=370)
   Male (n=139)
7.2
10.6
1.00 (reference)
1.53 (0.71-3.01) .22
30.5
22.0
1.00
0.64 (0.40-1.03) .06
--- ---
Age in years
   Not using (herbs or TCAM)
   Using (herbs or TCAM)
36.8(9.9)
34.5(9.1)
1.00
0.98 (0.95-1.02) .26
36.3(9.8
)
34.5(9.1
)
1.00
0.97 (0.95-1.00) .02
--- 1.00
0.98 (0.96-1.01) .156
Educational level
   Low (None-up to Grade 7)
   High (Grade 8 or more)
6.1
8.6
1.00
1.45 (0.72-2.93) .301
20.9
31.7
1.00
1.76 (1.16-2.67) .008
--- 1.00
1.67 (1.03-2.78) .049
Residence
Rural (n=388)    
Urban (n=227)    
9.8
5.1 0.39(0.18-0.88) .02
30.0
24.4
1.00
0.71 (0.46-1.10) .13
1.00
1.04 (0.44-
2.48)
.927
---
Employed
   No
   Yes
9.3
4.4
1.00
0.45 (0.17-1.17) .099
26.0
32.7
1.00
1.38 (0.88-2.18) 1.62
--- ---
Being on a disability grant 
(chronic illness including AIDS) 
(n=128)
   No 
   Yes 
5.0
10.9
1.00
2.34 (1.16-4.67) .02
30.1
25.7
1.00
0.80 (0.54-1.18) .26
1.00
2.45 (1.11-
5.41)
.026
---
Having a health insurance
   No 
  Yes 
9.0
2.6
1.00
0.27 (0.06-1.15) .08
28.7
22.4
1.00
0.71 (0.40-1.27) .26
---
CD4 count
    ≤200 
    >200 
9.1
2.4
1.00
0.24 (0.06-1.03) .06
26.7
33.3
1.00
1.37 (0.83-2.27) .22
---
Time since HIV diagnosis
    2006-1995
    2007/8   
8.9
7.2
1.00
0.79 (0.38-1.64) .53
32.0
25.7
1.00
0.74 (0.47-1.15) .18
---
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Hospital admission in past 6 
months
  No
  Yes
8.0
7.5
1.00
0.93 (0.32-2.73) .90
28.2
24.5
1.00
0.83 (0.43-1.60) .57
---
Number of HIV symptoms 
   Not using (herbs or TCAM)
   Using (herbs or TCAM)
M(SD)
1.21(2.4)
1.25(4.2)
1.00
1.01 (0.89-1.14) .93
M(SD
1.20(2.5
)
1.28(3.0
)
1.01 (0.94-1.09) .77
---
Overall Quality of Life (range 1-
5)
   Not using (herbs or TCAM)
   Using (herbs or TCAM)
4.4(0.7)
4.0(0.4)
1.00
0.49 (0.33-0.73) .000
4.4 (0.7)
4.1 (0.6)
1.00
0.50 (0.37-0.67) .000
1.00
0.97 (0.50-
1.89)
.937
1.00
0.59 (0.42-0.83) .003
Missed medication to avoid side 
effects
   No
   Yes
5.7
35.9
1.00
9.23 (4.31-19.75) .000
26.0
48.7
1.00
2.70 (1.40-5.23) .003
1.00
3.00 (1.24-
7.22)
.014
1.00
1.87 (0.85-4.14) .121
Suspended ART because of side 
effects
   No
   Yes
7.6
13.0
1.00
1.83 (0.52-6.44) .347
27.6
27.3
1.00
0.99 (0.38-2.57) .975
--- ---
Understanding of T-helper 
(CD4) count
  No or some
  Yes
4.1
9.9
1.00
2.53 (1.09-5.84) .030
35.7
24.0
1.00
0.57 (0.38-0.85) .006
1.00
0.96 (0.35-
2.64)
.934
1.00
0.54 (0.33-0.89) .016
HIV disease & HIV treatment 
related knowledge (better 
informed than most)
   No
   Yes
3.3
9.0
1.00
3.03 (1.06-8.68) .039
9.0
33.9
1.00
5.17 (2.68-9.94) .000
1.00
0.21 (0.04-
1.10)
.064
1.00
3.25 (1.51-7.01) .003
Information involvement score
   Low
   High
17.1
1.9
1.00
0.10 (0.04-0.23) .000
37.7
21.5
1.00
0.45 (0.31-0.67) .000
1.00
0.50 (0.12-
2.07)
.337
1.00
0.97 (0.52-1.83) .930
Degree of trust in medical 
provider score
   Low
   High
16.3
1.7
1.00
0.09 (0.03-0.23) .000
37.7
20.6
1.00
0.43 (0.29-0.64) .000
1.00
0.39 (0.08-
2.01)
.259
1.00
1.21 (0.64-2.30) .555
Decision involvement score
Peltzer et al.,  Afr. J. Trad. CAM (2010) 7 (2): 125 - 137 135
   Low
   High
1.7
16.0
1.00
10.84 (4.17-
28.18)
.000
17.4
41.6
1.00
3.37 (2.24-5.06) .000
1.00
2.50  (0.63-
9.96)
.195
1.00
3.71 (2.02-6.82) .000
Discrimination by care provider
   No
   Yes
7.7
14.3
1.00
2.00 (0.43-9.29) .374
28.0
21.4
1.00
0.70 (0.19-2.55) .588
--- ---
Seen ARV treatment buddy
   No
   Yes
2.4
24.4
1.00
13.36 (6.17-28.91 .000
25.6
34.6
1.00
1.54 (1.00-2.36) .049
1.00
5.27 (0.54-
51.15)
.152
1.00
0.70 (0.16-3.14) .641
Seen someone for 
counselling/support
   No
   Yes
2.6
25.2
1.00
12.80 (6.06-
27.06)
.000
25.5
35.2
1.00
1.59 (1.03-2.46) .037
1.00
0.85 (0.10-
7.49)
.846
1.00
0.65 (0.14-2.96) .575
Nagelkerke R Square .34 .23
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remedies after initiating ARVs appears to be a consistent finding. In Uganda for example, Langlois-Klassen and 
colleagues (2007) found that the use of traditional herbal remedies had declined from approximately 90% prior to 
HIV diagnosis to 53% amongst patients with HIV-related symptoms on ARVs. For patients on supportive treatment 
and not ARVs, this figure was higher at 63%. In a small cross-sectional study (N=44) of workplace clinic attendees 
in South Africa, only 23% of the 30 people taking ARVs reported current use of traditional medicine, despite 84% 
reporting use of traditional medicine in the past (Babb et al., 2007). Outside of Africa, similar results have been 
found. Agnoletto, Chiaffarino, Nasta and colleagues (2006) for example, reported that TCAM use was less common 
among respondents taking ARVs compared to those not on ARVs.
The reason for a reported decline in use of herbal medicine after initiating ARVs may in part be due to 
patients’ reluctance to disclose their use of herbal remedies, particularly as their physician’s advice against 
concomitant medicine use. In addition, ART naïve patients receive once they have been identified as possible ART 
candidates in South Africa, especially at our sample hospitals, training on correct ART adherence which discourages 
the use of herbal medicines (Ramlagan and Peltzer, 2008). In the present study most (95%) of the health care 
providers were not aware that their patients were taking herbal treatments. Similarly, Langlois-Klassenet al. (2008) 
found in Uganda that only 16% of respondents had informed their conventional medical practitioners about their use 
of herbs. According to the South African National ARV Treatment Guidelines (Department of Health, 2004) patients 
must disclose any over-the-counter drugs and traditional medicines due to the possibility of contraindications and 
adverse drug interactions. Caution is noted that TCAM use has the potential for adverse effects (Hsiao et al., 2003).
In the present study, a decline was also seen however in less controversial practices such as faith healing 
methods (including spiritual practices and prayer) and physical/body-mind therapies (exercise and massage), despite 
an increase in disclosure rates to providers. An alternative explanation may, therefore, be that improved physical 
well-being as a result of ARVs and improved understanding of adherence may have reduced the need for use of 
TCAM.
In the present study, the use of herbal treatments was associated with ARV non-adherence, which is 
confirmed from some other studies (e.g., Owen-Smith et al., 2007) as were the major self-reported reasons for non-
adherence ( “were away from home”, “wanted to avoid side effects”, “felt sick or ill” and “felt good”, (Golin et al., 
2002). In this study “having missed ARV medication to avoid side effects” and being on a disability grant were 
significant predictors for the use of herbal treatment for HIV. Agnoletto et al. (2006) also found that TCAM use was 
more common in outpatients who reported HAART-related side effects (specifically neuropathy). 
Higher education, lower quality of life, higher HIV disease and treatment related knowledge and higher 
health care decision involvement were significant predictors for TCAM use. These factors associated with TCAM 
use suggest that TCAM use may be associated with heightened awareness regarding the availability of such 
therapies, as found in other studies (Josephs et al., 2007).
Conclusion
High use of TCAM prior to ART seems to decline when starting ART. Herbal treatment for HIV was 
associated with non-adherence to ART and should be considered in ART adherence management. 
Limitations
One limitation of this study is that the data have only one time adherence data, thereby limiting our ability 
to be certain about the temporal relationship between TCAM use and HAART adherence. Future longitudinal cohort 
studies are needed to provide evidence for temporality. A second limitation is the self-report data for both TCAM use 
and HAART adherence. Finally, the findings are derived from a sample of men and women residing in one district in 
one province in South Africa. Thus caution is urged in generalizing the findings to other districts and provinces in 
the country.
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